Center Laboratories (ROCO:4123) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4123 Center Laboratories Inc ROCO:4123
69 GF Score
Price NT$37.50
GF Value NT$43.04
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Center Laboratories FFO?

FFO (Funds from operations) only applies to REITs.

ROCO:4123
69GF Score
Center Laboratories Inc ROCO:4123
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Center Laboratories (ROCO:4123) Overvalued in 2026?

Based on GuruFocus' analysis, Center Laboratories stock appears to be undervalued. The current stock price of NT$37.50 is trading 12.9% below its estimated GF Value™ of NT$43.04. GuruFocus considers Center Laboratories to be Modestly Undervalued.

Key valuation signals for ROCO:4123:

  • FFO:
  • GF Value™: NT$43.04 vs. price of NT$37.50 (12.9% below fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the ROCO:4123 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Center Laboratories Business Description

Address No. 3-2, Park Street, 7th floor, Nangang District, Taipei City, TWN, 115
Center Laboratories Inc is engaged in the manufacture and sale of various Western pharmaceuticals, including Western medicine manufacturing, wholesale, and retail. The Company operates through the following segments: Pharmaceutical Division, Biotechnology Venture Capital, and Glac Segment. The Pharmaceutical Division, which generates the majority of revenue, manufactures and sells various Western pharmaceuticals. The Biotechnology Venture Capital segment invests in domestic and foreign biotechnology undertakings, while the Glac Segment manufactures and sells probiotic products. The Company operates in Taiwan, Mainland China, and other regions, with Taiwan generating the majority of revenue.
69GF Score

Get the complete analysis for ROCO:4123

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$37.50
Price
NT$43.04
GF Value